Martin, Thomas G.
Myers, Valerie D.
Dubey, Praveen
Dubey, Shubham
Perez, Edith http://orcid.org/0000-0003-4980-5590
Moravec, Christine S.
Willis, Monte S.
Feldman, Arthur M.
Kirk, Jonathan A. http://orcid.org/0000-0002-5192-2860
Funding for this research was provided by:
American Heart Association (20PRE35170045)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL91799, HL12309, HL136737)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 3 May 2020
Accepted: 22 April 2021
First Online: 19 May 2021
Competing interests
: A.M.F. has equity in and is a director of Renovacor, Inc., a biotechnology company developing gene therapy for patients with BAG3 genetic variants. The other authors declare no competing interests.